Edwards Lifesciences Co. (NYSE:EW) Stock Holdings Trimmed by Foundry Partners LLC

Foundry Partners LLC lessened its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 6.3% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,325 shares of the medical research company’s stock after selling 225 shares during the period. Foundry Partners LLC’s holdings in Edwards Lifesciences were worth $219,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in EW. First Community Trust NA bought a new position in Edwards Lifesciences in the second quarter worth about $29,000. Webster Bank N. A. bought a new stake in shares of Edwards Lifesciences in the 2nd quarter worth approximately $39,000. Versant Capital Management Inc grew its stake in Edwards Lifesciences by 206.3% during the 2nd quarter. Versant Capital Management Inc now owns 484 shares of the medical research company’s stock worth $45,000 after buying an additional 326 shares during the last quarter. Prospera Private Wealth LLC acquired a new stake in Edwards Lifesciences in the third quarter worth $32,000. Finally, Avior Wealth Management LLC lifted its stake in Edwards Lifesciences by 138.7% in the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after buying an additional 308 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on EW shares. JPMorgan Chase & Co. increased their price objective on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a report on Friday, October 25th. Canaccord Genuity Group reduced their price objective on Edwards Lifesciences from $66.00 to $63.00 and set a “hold” rating for the company in a research report on Friday, October 25th. Robert W. Baird decreased their price objective on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a report on Friday, October 25th. The Goldman Sachs Group cut their target price on Edwards Lifesciences from $107.00 to $91.00 and set a “buy” rating on the stock in a research note on Friday, July 26th. Finally, UBS Group lowered their price target on Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating on the stock in a report on Tuesday, September 10th. Seventeen investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $75.67.

Insiders Place Their Bets

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total transaction of $327,850.00. Following the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $3,077,593.52. This represents a 9.63 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Larry L. Wood sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the sale, the insider now owns 198,526 shares of the company’s stock, valued at approximately $13,084,848.66. This trade represents a 11.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 40,000 shares of company stock valued at $2,657,000 over the last ninety days. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Trading Up 0.2 %

Edwards Lifesciences stock opened at $70.49 on Friday. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The company’s fifty day simple moving average is $67.70 and its 200-day simple moving average is $75.73. The stock has a market cap of $41.58 billion, a P/E ratio of 10.17, a P/E/G ratio of 3.95 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, hitting the consensus estimate of $0.67. The company had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The business’s revenue was up 8.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.59 EPS. As a group, sell-side analysts forecast that Edwards Lifesciences Co. will post 2.57 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.